Introduction
============

Heart failure is a primary cause of morbidity and mortality worldwide. As the most widely studied and commonly applied NP, BNP has the effects of diuresis, natriuresis, vasodilation, anti-hypertrophy and anti-fibrosis and it inhibits the renin-angiotensin-aldosterone and sympathetic nervous systems to maintain cardiorenal homeostasis and counteract the effects of HF ([@B64]). Both BNP and NT-proBNP are established as HF biomarkers and recommended by international guidelines ([@B71]; [@B26]). Although affected by age, gender, obesity, renal function, and other factors, plasma BNP levels are closely related to HF severity and applied as diagnostic, managing and prognostic tools for HF ([@B74]). However, due to the complexity of BNP system, the diversity of BNP forms and the heterogeneity of HF status, there are biochemical, analytical and clinical issues on BNP not fully understood ([@B34]).

Biochemical Issues
==================

The 134-aa preproBNP is synthesized in the cardiomyocytes, and 108-aa proBNP is then produced by removing a 26-aa signal peptide (**Figure [1](#F1){ref-type="fig"}**). Enzyme-mediated processing of proBNP produces BNP (32-aa) with mature function and NT-proBNP (76-aa), which are released into the blood when the ventricular wall is stretched because of increased pressure or volume overload ([@B52]; [@B67]). proBNP is degraded into NT-proBNP and BNP in a 1:1 ratio. NT-proBNP has no known bioactivity and is present at higher levels than BNP, perhaps due to slower clearance from blood ([@B2]).
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Corin and furin are the possible proBNP activating enzymes produced in the cardiomyocytes and both the soluble circulating and membrane-bound forms may be involved in proBNP processing ([@B10]). Corin and furin are present at the cell surface with the ability to process proBNP and have soluble forms in blood raising the possibility of proBNP processing in blood ([@B36]). Corin and furin may produce different BNP forms: BNP4-32 and BNP1-32, respectively ([@B66]). However, other enzymes cannot be excluded in humans ([@B38]; [@B28]). Soluble corin is significantly decreased in HF, reminding us that it may have an attenuated activation and be applied as a biomarker in HF ([@B49]). Moreover, corin and furin activation may correlate with BNP bioactivity, whereas their deficiency may correlate with hypertension and HF ([@B6]). Corin and furin overexpression may be beneficial in experimental HF models. Unprocessed proBNP has higher levels in patients with HF, suggesting that their activities are rate-limiting factors in HF ([@B29]). The various BNP forms have different cGMP activating properties and proBNP and NT-proBNP have reduced cGMP activities ([@B32]; [@B20]). However, there have been almost no studies with the specific purpose of assessing proBNP processing in blood ([@B9]). proBNP processing is significantly disturbed in HF and may be a novel target for drugs ([@B15]; [@B9]).

A disintegrin and metalloprotease 10 mediates corin shedding and decreases corin bioactivity at the cell surface ([@B36]). In humans, corin is expressed not only in the heart, but also in the kidney (proximal convoluted tubules and medullary collecting ducts) ([@B33]). In proximal tubular epithelial cells, corin is expressed in the apical membrane, whereas neprilysin is expressed in the brush border ([@B19]). Reduced renal corin expression and urine soluble corin in CKD may prevent local function of NPs ([@B23]). Reduced renal NP autocrine may contribute to NP resistance and further disturb cardiorenal homeostasis, if it is not compensated by increased cardiac NP endocrine ([@B19]). ADAM 10-mediated shedding may reduce corin levels in the kidney. Future studies are needed to analyze renal corin expression and ADAM 10-mediated shedding in patients with HF and/or CKD.

Proteolytic cleavage (Arg801-Ile802) may activate corin, with PCSK6 as an activating enzyme ([@B7]; [@B77]). Among nine members of proprotein convertase subtilisin/kexin (PCSK) family, PCSK6 overexpression can enhance corin activation. Meanwhile, selective PCSK6 gene silencing by small interfering RNAs can abolish corin activation. PCSK6 gene expression can be detected in cells expressing corin, and corin variants without the cleavage site for PCSK6 are resistant to PCSK6 activation ([@B78]). However, previous studies have demonstrated that not only proBNP levels, but also cardiac function and hypertrophy, cannot be changed by affecting either corin or PCSK6, in spite of reduced proANP levels and effective control of hypertension ([@B7]). PCSK family includes a series of serine endoproteases with many substrates. Other substrates of PCSK6 are cytokines of TGF-β family, nodal growth differentiation factor pro-protein and aggrecanases ([@B72]). Atrial natriuretic peptide (ANP) has an anti-hypertrophic effect on the heart through TGF-β signaling ([@B5]). PCSK6 may inhibit the cytokines of TGF-β family, and counteract the anti-hypertrophic effect of ANP. Another member of PCSK family, PCSK9, mediates degradation of low-density lipoprotein cholesterol and has been recommended as a target for a novel lipid-lowering drug ([@B50]). As a corin activating enzyme, PCSK6 may be a novel target for drugs in HF by mediating proBNP degradation and increasing endogenous BNP ([@B76]).

B-type natriuretic peptide is degraded by neprilysin, dipeptidyl peptidase-4 (DPP-4) and insulin-degrading enzyme (IDE) ([@B57]). Peptidyl arginine aldehyde protease has been shown to degrade BNP at the sites with arginine, because its inhibitors reduce BNP degradation ([@B3]). Meprin has been shown to degrade BNP in animals but not in humans. Whether other enzymes, including meprin, degrade BNP remains undetermined in humans ([@B16]). BNP is degraded by neprilysin at several sites, but not at these sites simultaneously. proBNP differs from BNP with a 76-aa N-terminal extension and may not be a substrate of neprilysin, suggesting potential effects of NP length and N-terminal extension on neprilysin degradation ([@B53]). Similarly, urodilatin is a N-terminal extended form of ANP and less rapidly degraded than ANP. D-type NP is not degraded and has the longest extension among NPs ([@B53]). Neither glycosylated nor non-glycosylated forms of proBNP are sensitive to neprilysin degradation, suggesting no effect of glycosylation on proBNP resistance to neprilysin. Moreover, BNP may be a poorer substrate of neprilysin than ANP ([@B17]). However, neprilysin has inconsistent effects on BNP degradation, perhaps because of different experimental conditions and race specificities.

Both proBNP and NT-proBNP are glycosylated in blood and the potential glycosylation sites are Thr36, Ser37, Ser44, Thr48, Ser53, Thr58, and Thr71 within the N-terminal region (aa residue 1--76), but not within the BNP (aa residue 77--108) ([@B63]). All these glycosylation sites are complete except Thr36 and Thr58 ([@B61]). NT-proBNP is glycosylated in the central region (aa residue 28--56), but not in the C-terminal region (aa residue 61--76) ([@B63]). proBNP is glycosylated not only in the central region, but also in the region near the cleavage site (aa residue 63--76) ([@B65]). Percentages of glycosylated proBNP and NT-proBNP are dependent on the individual. Patients with chronic HF, but not those with acute HF, have the highest percentage of glycosylated proBNP ([@B75]). Meanwhile, furin bioactivity, but not its levels, is greater in patients with acute HF than in those with chronic HF ([@B75]). proBNP processing may have different mechanisms: patients with acute HF have increased BNP production due to more acute fluid overload and patients with chronic HF have limited proBNP degradation due to less acute fluid overload. Glycosylation, especially at the Thr71 near the cleavage site, may inhibit corin- and furin-mediated degradation of proBNP in HF ([@B61]). This effect remains undetermined but may correlate with whether proBNP is processed in blood ([@B55]; [@B31]).

Analytical Issues
=================

Current NT-proBNP immunoassays have the same antibodies and calibrators from Roche^TM^ with small systematic differences ([@B13]). However, current BNP immunoassays (**Table [1](#T1){ref-type="table"}**) have different antibodies and calibrators with large systematic differences ([@B12]). The most common BNP immunoassays are sandwich immunoassays with two monoclonal or polyclonal antibodies binding to two separate epitopes: one binds to the ring structure to recognize the active form and the other binds to the N-terminal or C-terminal region ([@B25]). The one binding to the C-terminal region \[Shionogi^TM^ IRMA and Siemens ADVIA for the Centaur platform\] with same monoclonal antibodies (the epitope 27--32 and 14--21) may not recognize cleaved forms of BNP like BNP1-27, while the one binding to the N-terminal region \[Alere^TM^ and Beckman Coulter^TM^ Triage BNP assays with the same monoclonal (the epitope 5--13) and polyclonal (the possible epitope 1--10) antibodies\] may not recognize cleaved forms of BNP like BNP3-32 ([@B3]). The single-epitope sandwich (SES)-BNP^TM^ immunofluorescent assay needs only one epitope by two different monoclonal antibodies, including the first monoclonal antibody (24C5) binding to the epitope 11--17, which is the most stable within the ring structure, and the second monoclonal antibody (Ab-BNP2) binding to the immune complex (the epitope 11--17 and 24C5) ([@B70]). As a highly sensitive assay, it stabilizes the immune complex and increases epitope affinity but recognizes not only BNP forms, but also glycosylated and non-glycosylated forms of proBNP.

###### 

Antibodies and standard materials used in commercial B-type natriuretic peptide (BNP) immunoassays.

  Methods                                         Capture antibody                                                                             Detection antibody                                                                           Standard material
  ----------------------------------------------- -------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- -------------------
  Shionogi^TM^ immunoradiometric assay (IRMA)     COOH terminus (BC-203), murine monoclonal AB, aa 27--32                                      Ring structure (KY-hBNPII) (Shionogi), murine monoclonal AB                                  Synthetic BNP
  Siemens^TM^ ADVIA method for Centaur platform   COOH terminus (BC-203), murine monoclonal AB, aa 27--32                                      Ring structure (KY-hBNPII) (Shionogi), murine monoclonal AB                                  Synthetic BNP
  Alere^TM^ Triage                                NH~2~ terminus and part of the ring structure (Scios), murine monoclonal AB, aa 5--13        BNP (Biosite), murine omniclonal AB, epitope not characterized (probably N-terminus 1--10)   Recombinant BNP
  Beckman Coulter^TM^ Triage                      BNP (Biosite), murine omniclonal AB, epitope not characterized (probably N-terminus 1--10)   NH~2~ terminus and part of the ring structure (Scios), murine monoclonal AB, aa 5--13        Recombinant BNP
  Abbott^TM^ i-STAT                               NH~2~ terminus and part of the ring structure (Scios), murine monoclonal AB, aa 5--13        COOH terminus, murine monoclonal AB, aa 26--32                                               Synthetic BNP

aa, amino acid

.

Current BNP immunoassays substantially reflect total levels of proBNP and BNP forms ([@B41]). Although proBNP processing occurs before or during secretion, unprocessed proBNP is present in blood at even higher levels than BNP and represents a significant part of BNP immunoreactivity in healthy individuals and HF patients ([@B14]). Corin and furin cannot process all the proBNP when proBNP production is obviously increased in patients with HF, or proBNP glycosylation occurs before secretion, especially at the Thr71 ([@B9]). Because proBNP shares a 32-aa structure with BNP, proBNP can mediate physiological functions like BNP. However, as the predominant form of BNP immunoreactivity in HF, unprocessed proBNP has an obviously decreased physiological function compared with BNP ([@B41]). Meanwhile, due to the cleavage of amino-terminal dipeptide from BNP1-32 by DPP-4 and neprilysin, BNP3-32 and 5--32 are present in blood. BNP3-32 rather than BNP1-32 may be the predominant form of BNP ([@B69]). Compared with BNP1-32, other BNP forms, such as BNP3-32, BNP4-32, BNP5-32, BNP5-31, BNP1-27, BNP 1-26, and BNP 1-25, have an obviously decreased physiological function and increased degradation rate by neprilysin ([@B4]). However, due to race-specific proteases, BNP forms may have no effect on the resistance of human BNP to neprilysin ([@B4]). Current BNP immunoassays overestimate BNP1-32 levels, because they also recognize less active BNP forms ([@B40]).

Antibody detection of NT-proBNP and proBNP may also be affected by glycosylation ([@B55]). Glycosylation suppresses binding of antibodies and makes them lose immunoreactivity ([@B42]). Current NT-proBNP immunoassays cross-react with non-glycosylated proBNP, and do not detect glycosylated NT-proBNP and proBNP. NT-proBNP immunoassays may be improved by antibodies detecting glycosylated or non-glycosylated NT-proBNP and antibodies detecting NT-proBNP not affected by glycosylation ([@B58]). In current proBNP immunoassays, glycosylated proBNP cross-reacts more than non-glycosylated proBNP with BNP and NT-proBNP ([@B22]). There are inter-individual differences in NT-proBNP and proBNP glycosylation in patients with and without HF ([@B59]). The N- and C-terminal regions of NT-proBNP and BNP are degraded in blood, which occurs between Pro2-Leu3, Leu3-Gly4, Pro6-Gly7, and Pro75-Arg76 of NT-proBNP ([@B24]). Thus, detecting N- and C-terminal cleaved forms of BNP and NT-proBNP is another challenge and it is difficult to develop an antibody not affected by glycosylation or terminal cleavage.

A highly sensitive immunoassay for proBNP is not affected by proBNP glycosylation, because it has a capture monoclonal antibody binding to the epitope 26--32 of BNP and a detection monoclonal antibody binding to the epitope 13--20 of proBNP, neither of which are glycosylation sites ([@B62]). Another immunoassay for proBNP has no significant cross-reaction with both NT-proBNP and BNP, because it has a polyclonal antibody binding to BNP and a monoclonal antibody binding to the cleavage site of proBNP, an epitope only belonging to proBNP ([@B43]). Meanwhile, a radioimmunoassay for proBNP binds to the N-terminal of proBNP (the epitope 1--10) and recognizes both proBNP and NT-proBNP ([@B30]). Automated immunoassays specific for both proBNP and BNP1-32 may be useful to determine both production and bioactivity of BNP forms. Moreover, proBNP and BNP immunoassays have been combined to better predict poor prognosis in patients with HF ([@B21]). Two immunoassays can be simultaneously applied to the same sample. However, BNP1-32 immunoassays with chromatography and mass spectrometry are unsuitable for routine application and there is no commercially available immunoassay that can recognize only active BNP1-32 ([@B48]).

Neprilysin inhibition may have varied effects on plasma BNP levels as a result of different immunoassays. The N-terminal Met4-Phe5 is the initial cleavage site and no BNP immunoassay has any antibody binding to it. Another cleavage site is located within the ring structure (Arg17-Ile18), which is cleaved before other sites, such as Lys14-Met15, Gly23-Leu24, and Val28-Leu29, and BNP immunoassays (Shionogi^TM^ and Siemens^TM^) with antibodies binding to the epitopes 14--21 may be sensitive to neprilysin degradation ([@B11]). With only one epitope and without space between epitopes, SES-BNP^TM^ assay is not sensitive to neprilysin degradation.

Blood samples for BNP assays should be drawn only in plastic tubes because BNP is unstable in glass tubes due to kallikrein activation ([@B1]). EDTA plasma is the only recommended specimen for BNP assays and serum is the recommended specimen for NT-proBNP assays. There are significant differences between serum and plasma levels of NPs with various detection platforms. Anticoagulant type is also significant. BNP is stable during storage at room temperature for 24 h or at 30°C for 12 h. Protease inhibitor (aprotinin) can be added to increase BNP storage time. NT-proBNP is stable during storage in serum, heparinized plasma or EDTA plasma at room temperature or at 4°C for 72 h or at -80°C for up to 1 year ([@B20]). It is essential to validate the effect of freeze-thaw cycles on the stability of BNP and NT-proBNP assays ([@B1]).

Clinical Issues
===============

Point of care testing is performed near the patients outside of the central laboratory with a rapid turnaround ([@B34]). POCT for BNP and NT-proBNP can effectively facilitate not only home-monitoring and community-service outside of hospitals, but also emergency testing and BNP-guided therapy in hospitals ([@B8]). However, due to poor performance (particularly sensitivity and precision) compared with laboratory assays, POCT for BNP and NT-proBNP has not been finally approved by authoritative organizations and is not widely available for clinical application ([@B37]). POCT for BNP with untreated fingertip capillary whole blood (Alere^TM^ Heart Check) closely correlates with POCTs for BNP with venipuncture EDTA plasma (Alere^TM^ Triage) or EDTA whole blood (Abbott^TM^ i-STAT) ([@B44]; [@B56]). Abbott^TM^ i-STAT produces a result within 10 min, whereas Alere^TM^ Triage and Alere^TM^ Heart Check produces their results within 15 min. It remains undetermined whether POCTs have good correlation with and similar precision to laboratory assays ([@B68]). Abbott^TM^ i-STAT and Alere^TM^ Triage reduce HF diagnosis compared with laboratory assays ([@B39]). Both POCT and laboratory assays have systematic differences caused by cross-reaction with glycosylated or non-glycosylated forms ([@B11]).

In the emergency room, rapid assay for BNP and NT-proBNP can discriminate the origin of acute dyspnea (acute HF versus bronchial asthma) ([@B26]). A plasma NT-proBNP level of 300 pg/ml is appropriate for ruling out acute HF. Age-dependent cutoff levels of plasma NT-proBNP are appropriate for ruling in acute HF: 450 pg/ml in patients \<50 years of age, 900 pg/ml in patients ≥50 years of age, and 1800 pg/ml in patients \>75 years of age ([@B45]). Plasma BNP levels of 100 and 400 pg/ml are appropriate for ruling out and ruling in acute HF, respectively ([@B18]).

The recombinant form of BNP (nesiritide) has been applied as a conventional drug in HF. It is currently considered to improve clinical symptoms and cardiac function and has no effect on patient prognosis ([@B27]). An angiotensin receptor inhibitor and neprilysin inhibitor (ARNI, LCZ696) has been approved as a novel drug in HF by US Food and Drug Administration ([@B46]). Because LCZ696 affects plasma BNP levels through inhibiting BNP degradation by neprilysin, it makes plasma BNP levels not accurately reflect cardiac function and produces a challenge for using BNP as a biomarker, making HF diagnostically ambiguous and therapeutically misleading ([@B51]). It could be argued that NT-proBNP is insensitive to neprilysin degradation and therefore can be applied as a biomarker in patients with LCZ696. However, this assumption is based on a simplified model of a complex biological phenomenon, and more studies are essential to analyze this biological phenomenon. Due to the complexity of BNP system (proBNP and BNP forms), neprilysin inhibition does not have a straightforward effect on plasma BNP levels ([@B54]). It remains undetermined how LCZ696 affects plasma BNP and NT-proBNP levels. Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure (PARADIGM-HF) trial has shown that plasma BNP levels increase while plasma NT-proBNP levels decrease in patients with LCZ696. Angiotensin receptor inhibitor and neprilysin inhibitor (ARNI, LCZ696) may inhibit both BNP degradation and proBNP processing. Increased BNP levels may inhibit proBNP production and thus decreased NT-proBNP levels may not be caused by improved cardiac function. Moreover, beneficial effects of LCZ696 in HF may be accomplished by increasing plasma ANP and C-type natriuretic peptide (CNP) levels but not plasma BNP levels. However, considering the presence of BNP in blood and its sensitivity to neprilysin, a relatively modest increase in plasma BNP levels may also account for improved prognosis with LCZ696 in patients with HF ([@B47]). Several studies have realized improved mortality and admission with BNP-guided therapy ([@B73]). However, previous studies have yielded inconsistent results on NT-proBNP-guided therapy ([@B60]). Current randomized clinical trials on BNP-guided therapy may further evaluate BNP-guided therapy in patients with HF ([@B35]).

Conclusion
==========

B-type natriuretic peptide metabolism and its forms are complex and make assays particularly challenging, but critical to providing future insight into BNP application and HF heterogeneity. Current immunoassays cross-react to varying degrees with proBNP, NT-proBNP, and various BNP forms and cannot effectively differentiate between these forms. Moreover, current immunoassays have different results and may not accurately reflect cardiac function. It is essential to design assays that can recognize specific forms of BNP, NT-proBNP, and proBNP to obtain more clinical information. Considering the complexity of BNP system and the heterogeneity of HF status, not only the processing of proBNP (corin/furin) and BNP (neprilysin), but also the effects of glycosylation on proBNP processing and BNP assays, should be targeted in future studies to enhance their diagnostic, therapeutic and prognostic values.
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:   a disintegrin and metalloprotease
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